Overview of Nazomac-AF

What is Nazomac-AF?

Nazomac-AF is a fixed-dose combination nasal spray used for the management of symptoms associated with allergic rhinitis. It combines two different types of medications that work through distinct mechanisms to address nasal inflammation and allergic reactions.

Components and Classification

The formulation contains two active pharmacological agents:

Azelastine: A second-generation antihistamine. It works by blocking the action of histamine, a natural substance in the body that triggers allergic symptoms such as sneezing and itching.
Fluticasone Propionate: A corticosteroid. It functions by reducing inflammation and swelling within the nasal passages, addressing the underlying cause of congestion.

Therapeutic Use

This combination therapy is primarily indicated for patients who require both an antihistamine and a corticosteroid for the relief of moderate to severe allergic symptoms. It is used to manage both seasonal allergic rhinitis (such as hay fever) and perennial allergic rhinitis (year-round allergies caused by dust, pet dander, or mold).

By addressing multiple pathways of the allergic response, Nazomac-AF helps alleviate a broad spectrum of symptoms, including:

Nasal congestion and stuffiness
Runny nose and post-nasal drip
Sneezing
Itching of the nose and eyes

Unlike oral medications, this nasal spray delivers the active ingredients directly to the affected tissue, allowing for localized action with minimal systemic absorption.

What side effects are possible with Nazomac-AF?

Possible side effects and safety information

This section outlines the adverse reactions and safety characteristics of Nazomac-AF as documented in official government regulatory sources, such as the FDA and European SmPCs. The information is structured according to frequency and the body system affected.

Official Adverse Reactions and Frequencies

Side effects are categorized by how often they are officially documented:

Common Reactions (occurring in 1 to 10 users in 100): These include local effects such as epistaxis (nosebleeds) and nasal discomfort or irritation. Dysgeusia, a disturbance in taste, and headache are also frequently documented.
Uncommon to Rare Reactions: Dry nasal mucosa is categorized as uncommon. Rare reactions documented in official labeling include hypersensitivity reactions.

System-Organ Classifications and Serious Safety Concerns

Adverse reactions are grouped by the physiological system they affect, aligning with regulatory standards. Effects are documented across Nervous System Disorders (e.g., somnolence, headache) and Respiratory, Thoracic and Mediastinal Disorders (e.g., nasal septal perforation).

Serious Adverse Reactions are explicitly documented and typically associated with the long-term, continuous use of the corticosteroid component. These include the potential for ocular effects such as glaucoma or cataracts, and the risk of systemic corticosteroid effects, such as adrenal suppression. Nasal septal perforation is also a documented risk.

Population and Duration-Related Safety Notes

The official safety profile includes explicit notes for specific patient groups. For pediatric patients, the potential for growth velocity reduction with prolonged use of intranasal corticosteroids is documented. Caution and monitoring are advised for individuals with severe hepatic impairment. The risks of ocular and systemic effects are officially associated with long-term exposure to the medication.

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on descriptions and required actions documented in government regulatory sources, such as the FDA and EMA prescribing information.

Property	Official Regulatory Statement
Documented Overdose Presentations	Acute exposure may manifest as somnolence (drowsiness). Chronic excessive use, especially at very high dosages, is officially documented to lead to signs of Hypercorticism and Adrenal Suppression (HPA axis effects).
Physiological Systems Affected	Central Nervous System (CNS) for acute effects; Hypothalamic-Pituitary-Adrenal (HPA) Axis for chronic effects.
Dose-Related Factors	Chronic systemic risks are tied to prolonged, high-dose exposure, while acute systemic effects are generally unlikely.
Population-Specific Notes	Caution is advised in patients with severe liver disease due to potentially increased systemic exposure. Concurrent use with alcohol or CNS depressants may cause additional impairment of CNS performance.

Required Emergency Actions

Classification	Official Regulatory Statement
Immediate Help Required	Emergency services must be contacted immediately if acute overdose leads to signs such as seizure, collapse, or difficulty breathing. Contact the Poison Control Helpline for specific guidance following ingestion.
Management	Treatment is symptomatic and supportive. For confirmed chronic HPA axis effects, the mandated procedure is slow discontinuation of the nasal spray and controlled dose adjustment.
Antidote	No specific antidote is formally documented in the official regulatory information.

Connection to the Overall Overdose Profile

Regulatory documents define this overdose profile by distinguishing between acute CNS effects from Azelastine, which trigger immediate emergency actions, and the chronic, systemic risks from Fluticasone, which require medical monitoring and controlled dose adjustment.

Therapeutic Uses of Nazomac-AF

What Nazomac-AF Treats: Main Uses and Benefits

This medication is commonly used to help manage the symptoms associated with both Seasonal Allergic Rhinitis (hay fever) and Perennial Allergic Rhinitis in adults and pediatric patients 6 years and older. The combination is considered relevant for managing symptoms that may become more noticeable or disruptive when use of a single-agent intranasal antihistamine or glucocorticoid is not considered sufficient. It is applied across conditions where symptoms may intensify temporarily, such as those caused by allergens like pollen, dust mites, or pet dander.

The combination is applied across domains where additional symptomatic support is needed, helping to address multiple symptoms at once. It is used for managing symptom clusters that may become intense or disruptive, such as nasal congestion, stuffy nose, persistent sneezing, runny nose, nasal itching, and associated itchy or watery eyes. The goal is to provide supportive relief when symptoms interfere with routine activities and contributes to improved comfort during periods of heightened symptoms. This combination may help patients cope with symptom fluctuations.

Quick Fact: Relief for Nasal Obstruction

The medication is commonly used to help improve nasal airflow and enhanced breathing comfort by addressing the swelling and irritation within the nasal passages.

Eligibility and Restrictions for Use

Eligibility Scope

Nazomac-AF is established for use in adults and adolescents (12 years and older). It is also indicated for pediatric patients 6 years of age and older. Use is not recommended for children below 6 years, as safety and efficacy have not been established in that age group. Geriatric patients generally do not require dose adjustment.

Contraindications and Restrictions

The medicine is contraindicated in any patient with a known history of hypersensitivity to Azelastine, Fluticasone Propionate, or any non-active ingredients.

Use requires caution or is restricted in several populations. It should be avoided in patients with recent nasal trauma, surgery, or ulcers until healing is complete. Caution is mandated for individuals with severe hepatic impairment, active or quiescent infections like tuberculosis or ocular herpes simplex, and those with a history of glaucoma or cataracts.

Pregnancy and Lactation

For women who are pregnant or breastfeeding, use is generally not recommended and should only occur if the potential therapeutic benefit is determined to outweigh the potential risk, due to a lack of adequate safety data in these populations.

What should I know about interactions with other medicines?

The official interaction profile for Nazomac-AF (Azelastine / Fluticasone Propionate) is defined by both pharmacokinetic and pharmacodynamic risks associated with its active components. Regulatory documentation states that no pharmacokinetic interaction occurs between azelastine and fluticasone propionate when co-administered in this fixed-dose nasal spray.

Interaction Scope

Medicinal product categories with documented interactions include Potent Cytochrome P450 3A4 (CYP3A4) Inhibitors and Central Nervous System (CNS) Depressants. Specific interacting medicines listed in regulatory documents include the potent CYP3A4 inhibitor Ritonavir and substances such as alcohol.

The mechanistic basis for these interactions is two-fold: a pharmacokinetic interaction where CYP3A4 inhibition significantly increases the plasma concentration of fluticasone propionate, and a pharmacodynamic interaction where Azelastine's effect is augmented by other CNS depressants.

Co-administration with Ritonavir is officially classified as a Significant interaction and is restricted, often labeled as not recommended or to be avoided, due to the documented risk of systemic corticosteroid effects and reduced serum cortisol concentrations. Likewise, concurrent use of the drug with alcohol or other CNS depressants is restricted and should be avoided because of the risk of enhanced impairment of CNS performance. No mandatory dose-separation timing rules are specified for the known interactions. A population-specific note highlights that increased systemic exposure of fluticasone propionate is anticipated in patients with severe hepatic impairment.

Mechanism of Action

How Nazomac-AF Works: Mechanism of Action

Nazomac-AF operates through two distinct, complementary pharmacodynamic mechanisms. The rapid action is mediated by Azelastine, which acts as a selective competitive antagonist of the Histamine H1 Receptor ( H1 R) in the nasal mucosa. By physically occupying this target, Azelastine prevents histamine binding, thereby suppressing the immediate increase in local vascular permeability and nerve fiber stimulation. This results in the quick cessation of initial receptor-mediated physiological responses.

Simultaneously, the sustained action is driven by Fluticasone Propionate, a high-affinity agonist of the Glucocorticoid Receptor ( GR). Fluticasone binding initiates a genomic cascade where the GR complex translocates to the nucleus to perform Transrepression, inhibiting transcription factors like NF-kappa B. This action suppresses the synthesis of pro-inflammatory proteins (e.g., cytokines, chemokines) and limits inflammatory cell recruitment. This synergy establishes both the quick cessation of early signaling and the long-term reversal of the underlying inflammatory tissue state.

Dosage and Administration Information

Official Administration Guidelines for Nazomac-AF

Nazomac-AF is a combination nasal spray intended for intranasal use only. Consistent, regular application is necessary to achieve the maximum therapeutic benefit. It can be used without regard to meal times.

Dosing and Frequency

Age Group	Recommended Dosage	Frequency
Adults and Adolescents (12 years and older)	One spray in each nostril	Twice daily (morning and evening)
Children (Under 12 years)	Use is not recommended	Not applicable

Preparation and Procedure

Before the first use, or if the device has not been used for 14 or more days, the pump must be primed by releasing approximately six sprays until a fine mist appears. The bottle should be shaken gently before each use.

Blow the nose gently to clear the nasal passages.
Close one nostril and insert the spray tip into the other nostril.
Direct the spray toward the sides of the nostril, away from the central cartilage (septum).
Breathe in gently through the nose while pressing down on the pump to administer one spray.
Repeat this process for the other nostril.
Wipe the spray tip and replace the protective cap.

Missed Dose

If a dose is missed, it should be administered as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular dosing schedule. A double dose should never be taken to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Allergic Rhinitis

Clinical trials have investigated the fixed-dose combination of azelastine hydrochloride (an antihistamine) and fluticasone propionate (a corticosteroid) for the relief of symptoms related to seasonal and perennial allergic rhinitis. Studies examined the compound's observed activity profile in adult and pediatric cohorts (age six and older).

Key Trial Outcomes

Comparative randomized controlled trials (RCTs) reported that the combination was associated with greater improvements in the reflective Total Nasal Symptom Score (rTNSS), which includes sneezing, nasal itching, runny nose, and nasal congestion, compared to using either azelastine or fluticasone alone.

One randomized trial observed a mean difference in the rTNSS of approximately 38% with the combination, relative to the improvement seen with individual agents.
Data showed improvements in symptoms were observed earlier with the combination product compared to fluticasone propionate monotherapy.
Observed improvements extended to quality of life (QoL) parameters, as assessed by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

Safety and Tolerability Profile

The safety profile has been assessed in multiple studies, including long-term use (up to 52 weeks) in adults and adolescents, and 90-day continuous use in children.

Observed Adverse Events: Research reports indicated that the most commonly observed adverse events were minor in intensity and included epistaxis (nosebleed), headache, and a bitter or unpleasant taste (associated with azelastine).
Long-term Monitoring: The incidence of treatment-related adverse events with the combination product was generally comparable to that of fluticasone monotherapy, with no evidence of major safety concerns such as mucosal ulcerations or nasal septal perforations reported in long-term safety studies.

Frequently Asked Questions (FAQ)

Common questions about Nazomac-AF (FAQ)

Q: How long does it typically take to feel relief after starting Nazomac-AF?

Studies indicate that the combination product is associated with earlier relief of symptoms compared to the corticosteroid component used alone. This is because the antihistamine component, azelastine, provides a rapid action to quickly address immediate allergic responses. However, the full, sustained anti-inflammatory benefit is typically achieved as the corticosteroid component builds up over a few days of regular use.

Q: Is Nazomac-AF safe for long-term use?

Official information supports the use of Nazomac-AF in studies lasting up to 52 weeks in adults and adolescents. While the medication has been found tolerable in these long-term studies, official documents highlight that serious adverse effects, such as ocular effects (like glaucoma or cataracts) and adrenal suppression, are documented risks associated with the prolonged use of any intranasal corticosteroid. Regulatory notes indicate that monitoring may be advised for individuals during continuous long-term exposure.

Q: How long does the effect of one dose of Nazomac-AF last?

The recommended dosing schedule for Nazomac-AF for adults and adolescents is twice daily, administered once in the morning and once in the evening. This twice-daily regimen is used in clinical trials and is intended to provide coverage between the morning and evening application periods.

Q: Why does it take a few days for some people to notice the full effect?

Nazomac-AF contains two active components: an antihistamine for quick relief, and a corticosteroid (fluticasone) for long-term anti-inflammatory action. The full benefit, particularly the sustained reduction in nasal swelling and congestion, depends on the corticosteroid component. The anti-inflammatory action of the corticosteroid builds up gradually in the nasal lining and may require a few days of regular application to reach its maximum effect.

Q: Why do official documents mention consulting a doctor about eye changes while using Nazomac-AF?

This guidance relates to the corticosteroid component in Nazomac-AF. Official safety documents list ocular effects, specifically glaucoma and cataracts, as potential serious adverse reactions associated with the long-term, continuous use of intranasal corticosteroids. The inclusion of this caution is tied to the need for appropriate monitoring, particularly if a patient has pre-existing conditions or develops visual symptoms.

Q: What should I look out for that would indicate I need to stop using Nazomac-AF?

Regulatory documents list serious adverse reactions associated with the medicine, particularly with long-term use, such as nasal septal perforation, ocular effects (glaucoma/cataracts), or signs of adrenal suppression. In official safety documents, any serious or unexpected side effects are identified as requiring review by a healthcare provider.

Q: Does Nazomac-AF interact with common pain relievers like ibuprofen?

Regulatory drug interaction data for the active components (Azelastine and Fluticasone) does not generally list a known interaction with common over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen. The determination of using any concomitant medication is managed by a healthcare provider.

Q: Can I use Nazomac-AF with my regular allergy pills?

The official product label cautions against concurrent use with alcohol or other substances classified as Central Nervous System (CNS) depressants. This is due to the azelastine component, which can increase the risk of drowsiness when combined with these types of medicines. Full disclosure of all medicines, including allergy pills, allows a healthcare provider to determine the risk of combining them.

Q: How is Nazomac-AF different from other nasal sprays I see in the pharmacy?

Nazomac-AF is defined as a fixed-dose combination product. This means it contains two distinct active ingredients—an antihistamine and a corticosteroid—in a single spray. Most other common nasal sprays available contain only one active ingredient, which gives Nazomac-AF a dual-action approach to target both immediate allergy triggers and underlying inflammation.

Q: What is the difference between Nazomac-AF and a decongestant spray?

The mechanisms of action are entirely different. Nazomac-AF works by blocking histamine and reducing inflammation to treat allergic symptoms. Decongestant sprays, on the other hand, function by directly constricting blood vessels in the nose to reduce swelling, which, if used for too long, can be associated with rebound congestion.

Q: Does Nazomac-AF work for non-allergic nasal issues?

According to the official product indications, Nazomac-AF is specifically approved for the relief of symptoms related to seasonal and perennial allergic rhinitis. Its documented clinical efficacy and approved use are limited to treating these allergy-related nasal conditions.

Q: Is it possible to become dependent on Nazomac-AF if I use it for a long time?

The active ingredients in Nazomac-AF (the antihistamine and corticosteroid) are not associated with the risk of rebound congestion or physical dependence. Rebound congestion is a common issue seen with short-term, over-the-counter decongestant nasal sprays, a class to which Nazomac-AF does not belong.

Q: Are there known interactions with herbal supplements when taking Nazomac-AF?

Official regulatory information advises patients to disclose all medicines, vitamins, and herbal supplements to their healthcare provider before beginning treatment. While specific interactions may not be listed, certain herbal products can potentially influence the body's processing of the active ingredients, and full disclosure is generally required to ensure the safe use of the product.

Q: Can Nazomac-AF affect the results of an allergy skin test?

Yes, because Nazomac-AF contains an antihistamine (azelastine). Antihistamines are known to interfere with the skin prick test results. Due to this potential interference, the discontinuation of the nasal spray for a specified period is commonly discussed prior to a scheduled allergy skin test.

Q: Are there any dietary restrictions mentioned for people using Nazomac-AF?

The primary restriction mentioned in regulatory documentation relates to the consumption of alcohol due to the potential for enhanced drowsiness from the antihistamine component. Additionally, official information suggests avoiding consuming grapefruit or grapefruit juice while using the product, as it may affect the way the body processes the medication.

Q: What is the information on using Nazomac-AF for ear or sinus pressure?

The product is officially indicated for the nasal and ocular symptoms of allergic rhinitis. While the relief of nasal congestion that the product provides may sometimes help to alleviate related sinus pressure, the product is not specifically approved as a treatment for conditions involving the ear or non-allergic sinus infections.

Q: Can Nazomac-AF cause changes in appetite or weight?

Changes in appetite or weight are not listed among the common side effects. However, in rare instances associated with long-term use, the corticosteroid component may be linked to systemic effects. These effects, such as those related to adrenal suppression, have the potential to indirectly cause changes in appetite or weight.

How should Nazomac-AF be stored and disposed of?

How to Store and Dispose of Nazomac-AF

The storage of this Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray must strictly follow regulatory guidance to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F).
Protection	The spray must be protected from freezing and should not be refrigerated.
Container	Keep the container tightly closed and stored in its original outer carton in an upright position.
Shelf-Life	The maximum in-use shelf life is 6 months after the first spray.

Handling and Disposal

The product must be kept out of sight and reach of children and should be stored locked up. When disposing of unused or expired medicine, it is prohibited to flush the product into the sanitary sewer system or surface water. Disposal should be carried out through an approved waste disposal process, generally by asking a healthcare professional or pharmacist.

Nazomac-AF